U.S. Renal Care Begins Enrollment for VOICE Trial Evaluating Vafseo® Outcomes in CKD Dialysis Patients The VOICE trial, initiated by U.S. Renal Care, starts evaluating Vafseo® for treating anemia in dialysis patients, aiming for market launch in 2025.

U.S. Renal Care Begins Enrollment for VOICE Trial Evaluating Vafseo® Outcomes in CKD Dialysis Patients #United_States #Cambridge #Vafseo #Akebia_Therapeutics #CKD_dialysis